Author: Spuch, Carlos; López-GarcÃa, Marta; Rivera-Baltanás, Tania; RodrÃgues-AmorÃm, Daniela; Olivares, José M.
                    Title: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report  Cord-id: 7ye3nu3a  Document date: 2020_8_27
                    ID: 7ye3nu3a
                    
                    Snippet: Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we have treated six patients with severe COVID-19 infection with lithium carbonate. We found that lithium carbonate significantly reduced plasma reactive C-Protein levels, increased lymphocyte numbers and d
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we have treated six patients with severe COVID-19 infection with lithium carbonate. We found that lithium carbonate significantly reduced plasma reactive C-Protein levels, increased lymphocyte numbers and decreased the neutrophil-lymphocyte ratio, improving both inflammatory activity and the immune response in these patients. We propose that lithium carbonate may deserve a place in the treatment against COVID-19.
 
  Search related documents: 
                                Co phrase  search for related documents- acute episode and lymphocyte ratio: 1
  - adenosine triphosphate and low middle: 1
  - lopinavir hydroxychloroquine and lymphocyte count: 1, 2
  - lopinavir hydroxychloroquine and lymphocyte neutrophil: 1, 2
  - lopinavir hydroxychloroquine and lymphocyte ratio: 1
  - lopinavir ritonavir and low middle: 1, 2, 3
  - lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  - lopinavir ritonavir and lymphocyte increase: 1
  - lopinavir ritonavir and lymphocyte level: 1, 2, 3
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date